ClinicalTrials.gg
RecruitingNCT07851025TREVI-OC-02Updated Nov 6, 2026

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

A Phase 3 interventional study of Torvutatug samrotecan and Bevacizumab in Epithelial Ovarian Cancer, sponsored by AstraZeneca. Recruiting at 220 sites in 29 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 6, 2026First sites in 5 new countriesSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
950
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Carcinoma, Ovarian Epithelial with a site in China — 30 open to participants now, 37 under way, 12 of them phase 3. Carcinoma, Ovarian Epithelial · China.

Planned enrollment
3rd of 53
950 · median 94
Started
2026
with 9 others
Phase 3
20 of 71
8 open now
Primary completion
2030-06
later than 34 of 36 live
Registered
70th of 71
by date
Lead sponsor
3 of 71
AstraZeneca

Among the 71 studies in Carcinoma, Ovarian Epithelial with a site in China, this one is the 3rd largest by planned enrollment of the 53 interventional ones that give a count, is one of 10 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 34 of the 36 other live ones, and was the 70th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

30 of the 71 studies in Carcinoma, Ovarian Epithelial with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carcinoma, Ovarian Epithelial with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.

Read the detailed description

This study aims to see if maintenance treatment with torvu-sam in combination with bevacizumab allows patients to live longer without the cancer getting worse, compared to patients receiving bevacizumab.

Eligible patients will be those with advanced ovarian cancer who have not progressed following completion of first-line platinum-based chemotherapy (PBC) and bevacizumab.

03

Conditions studied

  • Epithelial Ovarian Cancer

Keywords

  • Epithelial ovarian cancer
  • Fallopian tube cancer
  • Primary peritoneal cancer
  • Folate receptor alpha
  • Antibody-drug conjugate
  • TREVI-OC-02
  • Torvutatug samrotecan
  • Torvu-sam
  • Homologous recombination deficiency (HRD)
  • Non-HRD positive
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with newly diagnosed FIGO Stage III/IV, confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma
  • Provision of an archival FFPE tumour sample
  • Participants who have completed at least 6 cycles and a maximum of 8 cycles of Platinum-based chemotherapy (PBC) prior to randomisation
  • Participants must have received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of PBC, prior to randomisation
  • Participants who have completed cytoreductive surgery or have inoperable disease
  • Participants with non-progressive disease upon completion of front-line induction therapy

Key Exclusion Criteria:

  • Participants with tumours of non-epithelial origin, borderline tumours, or low-grade epithelial tumours
  • BRCA1/2 mutation (germline or somatic) or HRD positive, unknown, or inconclusive tumour status
  • Participants with history of (non-infectious) ILD/pneumonitis that required or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
  • Participants with non-healing wound, active ulcer, or bone fracture
  • Participants with evidence of active or ongoing bowel obstruction
  • Prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
950 participants (estimated)

Study arms

  • Experimental
    Torvutatug samrotecan + Bevacizumab

    Torvutatug samrotecan IV (intravenous) + Bevacizumab IV

    Drug: Torvutatug samrotecan · Drug: Bevacizumab

  • Active comparator
    Bevacizumab

    Bevacizumab IV

    Drug: Bevacizumab

Interventions

  • Antibody drug conjugate

    Also known as: AZD5335, Torvu-sam

  • Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor

    Also known as: Avastin, Vegzelma

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to radiographic progression as assessed by BICR per RECIST v1.1, or death due to any cause.

    Time frame: up to approximately 5 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization until the date of death due to any cause.

    Time frame: up to approximately 7 years

  2. Second progression free survival (PFS2)

    PFS2 is defined as time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression) after first subsequent therapy, or death.

    Time frame: up to approximately 5 years

  3. Time to First Subsequent Therapy (TFST)

    TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.

    Time frame: up to approximately 7 years

  4. Time to Second Subsequent Therapy (TSST)

    TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.

    Time frame: up to approximately 7 years

  5. Health-related Quality of Life (HrQoL)

    Change from baseline and time to deterioration in global health status/quality of life (GHS/QoL), physical functioning (PF), and ovarian cancer symptoms (EORTC IL433).

    Time frame: up to approximately 5 years

  6. Number and percentage of participants with adverse events as graded by CTCAE v6 criteria

    Adverse Event Incidence

    Time frame: up to approximately 7 years

07

Study locations

4 of 220 sites recruiting
  • Research Site
    Tamarac, Florida 33321, United States
    Not yet recruiting
  • Research Site
    Tampa, Florida 33606, United States
    Not yet recruiting
  • Research Site
    Baton Rouge, Louisiana 70808, United States
    Not yet recruiting
  • Research Site
    Baltimore, Maryland 21201, United States
    Not yet recruiting
  • Research Site
    Billings, Montana 59106, United States
    Not yet recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Research Site
    Buenos Aires, C1122AAL, Argentina
    Not yet recruiting
  • Research Site
    Buenos Aires, C1125ABD, Argentina
    Not yet recruiting
  • Research Site
    Capital Federal, 1118, Argentina
    Not yet recruiting
  • Research Site
    Ciudad de Buenos Aires, 1015, Argentina
    Not yet recruiting
  • Research Site
    Ciudad de Buenos Aires, 1426, Argentina
    Not yet recruiting
  • Research Site
    Córdoba, X5000AAW, Argentina
    Not yet recruiting
  • Research Site
    Córdoba, X5000HXK, Argentina
    Not yet recruiting
  • Research Site
    Córdoba, X5008HHW, Argentina
    Not yet recruiting
  • Research Site
    Rosario, S2000KZE, Argentina
    Not yet recruiting
  • Research Site
    Salta, A4400EMI, Argentina
    Not yet recruiting
  • Research Site
    Santa Fe, S2002RE, Argentina
    Not yet recruiting
  • Research Site
    Viedma, R8500ACE, Argentina
    Not yet recruiting
  • Research Site
    Auchenflower, 4066, Australia
    Recruiting
  • Research Site
    Benowa, 4217, Australia
    Not yet recruiting
  • Research Site
    Hobart, 7000, Australia
    Not yet recruiting
  • Research Site
    Kingswood, 2747, Australia
    Not yet recruiting
  • Research Site
    Nedlands, 6009, Australia
    Not yet recruiting
  • Research Site
    Port Macquarie, 2444, Australia
    Not yet recruiting
  • Research Site
    Randwick, 2031, Australia
    Not yet recruiting
  • Research Site
    Richmond, 3121, Australia
    Not yet recruiting
  • Research Site
    Toorak Gardens, 5065, Australia
    Not yet recruiting
  • Research Site
    Wollongong, 2500, Australia
    Not yet recruiting
  • Research Site
    Woodville, 5011, Australia
    Not yet recruiting
  • Research Site
    Fortaleza, 60336-045, Brazil
    Not yet recruiting
  • Research Site
    Itajaí, 88301-220, Brazil
    Not yet recruiting
  • Research Site
    Jaú, 17210-080, Brazil
    Not yet recruiting
  • Research Site
    Natal, 59075-740, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90020-090, Brazil
    Not yet recruiting
  • Research Site
    Rio de Janeiro, 20230-130, Brazil
    Not yet recruiting
  • Research Site
    Salvador, 41253-190, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01317-000, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01409-902, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 04014-002, Brazil
    Not yet recruiting
  • Research Site
    Dobrich, 9300, Bulgaria
    Not yet recruiting
  • Research Site
    Plovdiv, 4000, Bulgaria
    Not yet recruiting
  • Research Site
    Shumen, 9700, Bulgaria
    Not yet recruiting
  • Research Site
    Sofia, 1330, Bulgaria
    Not yet recruiting
  • Research Site
    Sofia, 1407, Bulgaria
    Not yet recruiting
  • Research Site
    Sofia, 1797, Bulgaria
    Not yet recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
  • Research Site
    Santiago, 7520426, Chile
    Not yet recruiting
  • Research Site
    Santiago, Chile
    Not yet recruiting
  • Research Site
    Temuco, 4780000, Chile
    Not yet recruiting
  • Research Site
    Viña del Mar, 2540364, Chile
    Not yet recruiting
  • Research Site
    Anyang, 455000, China
    Not yet recruiting
  • Research Site
    Beijing, 100034, China
    Not yet recruiting
  • Research Site
    Beijing, 100036, China
    Not yet recruiting
  • Research Site
    Beijing, 100210, China
    Not yet recruiting
  • Research Site
    Beijing, 100730, China
    Not yet recruiting
  • Research Site
    Binzhou Shi, 256603, China
    Not yet recruiting
  • Research Site
    Changchun, 130021, China
    Not yet recruiting
  • Research Site
    Changsha, 410013, China
    Not yet recruiting
  • Research Site
    Chengdu, 610072, China
    Not yet recruiting
  • Research Site
    Chongqing, 400030, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350014, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510080, China
    Not yet recruiting
  • Research Site
    Haikou, 570311, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310003, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310022, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310052, China
    Not yet recruiting
  • Research Site
    Hefei, 230031, China
    Not yet recruiting
  • Research Site
    Huangpu District, 200025, China
    Not yet recruiting
  • Research Site
    Jinan, 250021, China
    Not yet recruiting
  • Research Site
    Jinan, 250117, China
    Not yet recruiting
  • Research Site
    Linyi, 276001, China
    Not yet recruiting
  • Research Site
    Luoyang, 471003, China
    Not yet recruiting
  • Research Site
    Luzhou, 646000, China
    Not yet recruiting
  • Research Site
    Nanchang, 330006, China
    Not yet recruiting
  • Research Site
    Nanjing, 210000, China
    Not yet recruiting
  • Research Site
    Nanjing, 210009, China
    Not yet recruiting
  • Research Site
    Nanning, 530021, China
    Not yet recruiting
  • Research Site
    Neijiang, 641000, China
    Not yet recruiting
  • Research Site
    Shanghai, 200011, China
    Not yet recruiting
  • Research Site
    Shanghai, 200032, China
    Not yet recruiting
  • Research Site
    Shantou, China
    Not yet recruiting
  • Research Site
    Shenzhen, 518039, China
    Not yet recruiting
  • Research Site
    Shijiazhuang, 050000, China
    Not yet recruiting
  • Research Site
    Suzhou, 215004, China
    Not yet recruiting
  • Research Site
    Taiyuan, 030013, China
    Not yet recruiting
  • Research Site
    Weifang, 261000, China
    Not yet recruiting
  • Research Site
    Wenzhou, 325015, China
    Not yet recruiting
  • Research Site
    Wuhan, 430060, China
    Not yet recruiting
  • Research Site
    Xinxiang, 453100, China
    Not yet recruiting
  • Research Site
    Xuzhou, 221009, China
    Not yet recruiting
  • Research Site
    Bogotá, 110221, Colombia
    Not yet recruiting
  • Research Site
    Bogotá, Colombia
    Not yet recruiting
  • Research Site
    Medellín, 050030, Colombia
    Not yet recruiting
  • Research Site
    Medellín, 50018, Colombia
    Not yet recruiting
  • Research Site
    Pasto, 520002, Colombia
    Not yet recruiting
  • Research Site
    Tartu, 51014, Estonia
    Not yet recruiting
  • Research Site
    Brest, 29200, France
    Not yet recruiting
  • Research Site
    Dijon, 21000, France
    Not yet recruiting
  • Research Site
    Lyon, 69008, France
    Not yet recruiting

Showing the first 100 of 220 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2030, 45 months after the start.

Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 1, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Jun 28, 2030
CompletionEst.
Aug 29, 2033
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
34 sites added — first sites in Estonia, France, Georgia, Poland and United Kingdom. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Research Site · Auchenflower, AustraliaNot yet recruiting→Recruiting
  • Research Site · Haifa, IsraelNot yet recruiting→Recruiting
  • Research Site · Jerusalem, IsraelNot yet recruiting→Recruiting
Show 34 added (7 France, 4 China, 3 Georgia, 3 Greece, 3 Italy, 2 United States, 2 Germany, 2 Spain, 1 Australia, 1 Colombia, 1 Estonia, 1 India, 1 Philippines, 1 Poland, 1 Slovakia, 1 United Kingdom)
  • Research Site · Tamarac, United States
  • Research Site · Baton Rouge, United States
  • Research Site · Woodville, Australia
  • Research Site · Anyang, China
  • Research Site · Luoyang, China
  • Research Site · Nanning, China
  • Research Site · Shantou, China
  • Research Site · Medellín, Colombia
  • Research Site · Tartu, Estonia
  • Research Site · Brest, France
  • Research Site · Dijon, France
  • Research Site · Lyon, France
  • Research Site · Marseille, France
  • Research Site · Paris, France
  • Research Site · Saint-Priest-en-Jarez, France
  • Research Site · Toulouse, France
  • Research Site · Batumi, Georgia
  • Research Site · Tbilisi, Georgia
  • Research Site · Tbilisi, Georgia
  • Research Site · Berlin, Germany
  • Research Site · Düsseldorf, Germany
  • Research Site · Athens, Greece
  • Research Site · Rio, Greece
  • Research Site · Thessaloniki, Greece
  • Research Site · New Delhi, India
  • Research Site · Milan, Italy
  • Research Site · Milan, Italy
  • Research Site · Parma, Italy
  • Research Site · Manila, Philippines
  • Research Site · Olsztyn, Poland
  • …and 4 more on the registry record
Nov 6, 2026
Primary completion
Jun 18, 2030→Jun 28, 2030
Nov 6, 2026
Study completion
Aug 17, 2033→Aug 29, 2033
Nov 6, 2026
Eligibility
1 criterion added, 1 removed
What changed in the criteria
  • RemovedHRD negative tumour
  • AddedBRCA1/2 mutation (germline or somatic) or HRD positive, unknown, or inconclusive tumour status
Nov 6, 2026
Title
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) NegativePositive Advanced Epithelial Ovarian Cancer
Nov 6, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Nov 6, 2026
    34 sites added — first sites in Estonia, France, Georgia, Poland and United Kingdom. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Research Site · Auchenflower, AustraliaNot yet recruiting→Recruiting
    • Research Site · Haifa, IsraelNot yet recruiting→Recruiting
    • Research Site · Jerusalem, IsraelNot yet recruiting→Recruiting
    Show 34 added (7 France, 4 China, 3 Georgia, 3 Greece, 3 Italy, 2 United States, 2 Germany, 2 Spain, 1 Australia, 1 Colombia, 1 Estonia, 1 India, 1 Philippines, 1 Poland, 1 Slovakia, 1 United Kingdom)
    • Research Site · Tamarac, United States
    • Research Site · Baton Rouge, United States
    • Research Site · Woodville, Australia
    • Research Site · Anyang, China
    • Research Site · Luoyang, China
    • Research Site · Nanning, China
    • Research Site · Shantou, China
    • Research Site · Medellín, Colombia
    • Research Site · Tartu, Estonia
    • Research Site · Brest, France
    • Research Site · Dijon, France
    • Research Site · Lyon, France
    • Research Site · Marseille, France
    • Research Site · Paris, France
    • Research Site · Saint-Priest-en-Jarez, France
    • Research Site · Toulouse, France
    • Research Site · Batumi, Georgia
    • Research Site · Tbilisi, Georgia
    • Research Site · Tbilisi, Georgia
    • Research Site · Berlin, Germany
    • Research Site · Düsseldorf, Germany
    • Research Site · Athens, Greece
    • Research Site · Rio, Greece
    • Research Site · Thessaloniki, Greece
    • Research Site · New Delhi, India
    • Research Site · Milan, Italy
    • Research Site · Milan, Italy
    • Research Site · Parma, Italy
    • Research Site · Manila, Philippines
    • Research Site · Olsztyn, Poland
    • …and 4 more on the registry record
    Primary completion Jun 18, 2030→Jun 28, 2030
    Study completion Aug 17, 2033→Aug 29, 2033
    Eligibility 1 criterion added, 1 removed
    What changed in the criteria
    • RemovedHRD negative tumour
    • AddedBRCA1/2 mutation (germline or somatic) or HRD positive, unknown, or inconclusive tumour status
    Title Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) NegativePositive Advanced Epithelial Ovarian Cancer
    + 4 other changes: verification date, description, conditions and arm descriptions
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851025
Lead sponsor
AstraZeneca
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Sep 16, 2026
Primary completion
Jun 28, 2030 (estimated)
Completion
Aug 29, 2033 (estimated)
Last update
Nov 6, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Torvutatug samrotecan

Start the discussion